Research
Hormonal
Dual GLP-1/GIP agonist tirzepatide (10-15 mg/week) produces superior weight loss (approx. 20.2%) compared to semaglutide (2.4 mg/week, approx. 13.7%) in patients with obesity.
If you are struggling with obesity and other treatments have failed, ask your doctor about tirzepatide. It is a weekly injection that targets hunger hormones and has been shown to produce greater weight loss than semaglutide. Be prepared for potential stomach issues, which usually improve over time, especially if the dose is increased slowly.
StrongSupportsVERY_HIGH confidence
SURMOUNT-5 (2025): comparison: tirzepatide 10–15 mg vs semaglutide 2.4 mg, tirzepatide: –20.2% vs semaglutide: –13.7% (P < 0.001)
Why this rating
Based on Phase III randomized clinical trials (SURMOUNT-5).
Source
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Marta Grycan et al. · Biuletyn Głównej Biblioteki Lekarskiej · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →